Press Release: Fortress Acquires Infra Pipe Solutions, Leading Manufacturer of HDPE Pipes and Structures
A. G. P.はフォートレス・バイオテック(FBIO.US)のレーティングを強気に据え置き、目標株価を4ドルに引き下げた
A. G. P.のアナリストScott Henryは$Fortress Biotech(FBIO.US)$のレーティングを強気に据え置き、目標株価を5ドルから4ドルに引き下げた。TipRanksのデータによると、このアナリストの最近1年間の的中率は40.0%、平均リターンは-1.0%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する情報を提供
HC Wainwright & Co. Maintains Buy on Fortress Biotech, Raises Price Target to $26
Fortress Biotech Analyst Ratings
Fortress Biotech GAAP EPS of -$0.76 Misses by $0.17, Revenue of $14.62M
10-Q:Q3 2024 四半期報告書
8-K:フォートレス・バイオテクノロジーが2024年第3四半期の決算と最近の企業ハイライトを報告
Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q3 Revenue $14.6M
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Press Release: Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Journey Medical 3Q Loss/Shr 12c >DERM
Mustang Bio Receives Positive Listing Determination From Nasdaq
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 Oncolytic Virus) to Treat Malignant Glioma
Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 31%
Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
Airspan Completes Strategic Transition for Long-Term Success, Secures $85.4 Million in New Equity Financing
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
Fortress Biotech Files to Sell 6.19M Shares of Common Stock for Holders
Fortress Biotech to Participate in October 2024 Investor Conferences